| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| ACCOUNTING FEES | 16,500 | 8,250 | 0 |
| Name | Date Acquired | How Acquired | Date Sold | Purchaser Name | Gross Sales Price | Basis | Basis Method | Sales Expenses | Total (net) | Accumulated Depreciation |
|---|---|---|---|---|---|---|---|---|---|---|
| UNRELATED BUSINESS INCOME SHORT-TERM CAPITAL GAINS FROM PARTNERSHIPS | PURCHASED | 69 | COST | 0 | 69 | |||||
| UNRELATED BUSINESS INCOME SHORT-TERM CAPITAL GAINS FROM PARTNERSHIPS | PURCHASED | 640 | COST | 0 | 640 |
| Identifier | Return Reference | Explanation |
|---|---|---|
| DONOR ADVISED FUNDS | FORM 990-PF, PART VII-A, LINE 12 | CONTRIBUTIONS TOTALING $788,000 WERE MADE BETWEEN JULY 1, 2023 AND JUNE 30, 2024 TO A DONOR ADVISED FUND AT CHATTANOOGA CHRISTIAN COMMUNITY FOUNDATION (DBA THE GENEROSITY TRUST), EIN# 62-1536731; WITH $788,000 BEING DISTRIBUTED IN THE SAME FISCAL YEAR. THE TRUST RETAINED ADVISORY PRIVILEGES. CHATTANOOGA CHRISTIAN COMMUNITY FOUNDATION ("CCCF") IS A SECTION 509(A)(1) ORGANIZATION AS REFERRED TO IN SECTION 170(B)(1)(A)(VI). THE ENTIRE AMOUNT WAS TREATED AS A QUALIFYING DISTRIBUTION IN PART XV, LINE 3, CONTRIBUTIONS, GIFTS, GRANTS PAID (STATEMENT #16). THE DONOR-ADVISED FUND AGREEMENT BETWEEN THE HUGH AND CHARLOTTE MACLELLAN CHARITABLE TRUST AND CCCF INCLUDES THE FOLLOWING:"CCCF SHALL RECEIVE, REVIEW AND CONSIDER WRITTEN RECOMMENDATIONS FROM THE COMMITTEE CONCERNING GRANTS MADE FROM THE FUND AND ANY CONDITIONS WHICH SHOULD BE PLACED UPON SUCH GRANTS. THE FINAL DECISION CONCERNING SUCH MATTERS SHALL BE MADE BY THE BOARD OF DIRECTORS OF CCCF.""NO INCOME OR PRINCIPAL OF THE FUND SHALL BE USED FOR ANY PURPOSE OR PAID TO ANY BENEFICIARY IF SUCH USE OR PAYMENT WOULD NOT BE PERMITTED BY THE INTERNAL REVENUE CODE (THE "CODE") OR REGULATIONS THEREUNDER FOR AN ORGANIZATION DESCRIBED IN SECTION 501(C)(3) OF THE CODE, TO WHICH CONTRIBUTIONS ARE DEDUCTIBLE UNDER SECTION 170(C)(2) OF THE CODE." |
| Name of Stock | End of Year Book Value | End of Year Fair Market Value |
|---|---|---|
| FRANCIS MEDICAL 8110 SHARES COMMON STOCK | 269,001 | 8,110 |
| UBS 3556 | 157,527 | 184,015 |
| UBS 4301 | 177,035 | 187,224 |
| UBS 5653 | 183,992 | 190,552 |
| UBS 5654 | 286,029 | 303,107 |
| UBS 5656 | 513,218 | 684,353 |
| UBS 5657 | 235,043 | 265,775 |
| UBS 5658 | 566,053 | 577,655 |
| UBS 5659 | 275,371 | 251,942 |
| UBS 5817 | 456,405 | 561,370 |
| UBS 6394 | 468,997 | 470,145 |
| UBS C0045 | 192,988 | 227,201 |
| Category/ Item | Listed at Cost or FMV | Book Value | End of Year Fair Market Value |
|---|---|---|---|
| AD FUND I, A SERIES OF PATHBREAKER SPV, LP | AT COST | 1,485,249 | 0 |
| AERIAL BIOPHARMA, LLC | AT COST | 394,457 | 0 |
| ARRIVO BIOVENTURES, LLC | AT COST | 300,101 | 1,404,220 |
| BI FUND I, A SERIES OF PATHBREAKER SPV, LP2 | AT COST | 50,432 | 767,914 |
| BOW RIVER CAPITAL 2017-QP FUND, LP | AT COST | 195,276 | 50,432 |
| C-III RECOVERY FUND II LP | AT COST | 0 | 201,011 |
| DE FUND I, A SERIES OF PATHBREAKER SPV, LP | AT COST | 385,161 | 0 |
| DYNAMO FUND I, LP | AT COST | 400,783 | 2,856,355 |
| DYNAMO FUND II, LP | AT COST | 324,510 | 532,284 |
| DYNAMO OPPORTUNITY FUND I, LP | AT COST | 12,685 | 682,801 |
| DYNAMO SVT ROBOTICS SPV II, LLC | AT COST | 202,383 | 12,407 |
| DYNAMO-GATIK LLC | AT COST | 59,118 | 89,122 |
| DYNAMO-SKUPOS, LLC2 | AT COST | 100,265 | 59,593 |
| DYNAMO-STORD SPV II, LLC | AT COST | 37,670 | 416,362 |
| DYNAMO-VECTOR, LLC | AT COST | 198,223 | 57,187 |
| ESO VENTURE FUND V, LP | AT COST | 116,742 | 252,440 |
| FR FUND I, A SERIES OF PATHBREAKER SPV II, LP | AT COST | 8,110 | 116,742 |
| FULCRUM GROWTH FUND III QP, LLC | AT COST | 813,060 | 502,401 |
| GOLUB CAPITAL PARTNERS INTERNATIONAL II, LP | AT COST | 283,647 | 1,780,922 |
| GOODWATER CAPITAL IV L.P. | AT COST | 402,144 | 258,505 |
| GOODWATER INFINITY II, LP | AT COST | 76,091 | 417,114 |
| GR FUND I, A SERIES OF PATHBREAKER SPV II, LP | AT COST | 207,635 | 76,091 |
| H20EY | AT COST | 504,617 | 212,529 |
| H2OEY VENTURES II, LLC | AT COST | 380,714 | 510,000 |
| HARBINGER CAPITAL PARTNERS SPECIAL SITUATIONS FUND | AT COST | 51,349 | 4,181 |
| HY FUND III, A SERIES OF PATHBREAKER SPV, LP | AT COST | 100,185 | 50,328 |
| IR B FUND, A SERIES OF PATHBREAKER SPV, LP | AT COST | 50,057 | 0 |
| IR C, A SERIES OF PATHBREAKER SPV, LP | AT COST | 35,493 | 0 |
| IR-1027 FUND IV, A SERIES OF PATHBREAKER SPV, LP | AT COST | 55,925 | 35,827 |
| IRON OX CN STAR, LP | AT COST | 100,000 | 7,552 |
| KERN CAPITAL LLC | AT COST | 25,000 | 100,000 |
| KERN DIAGNOSTICS LLC | AT COST | 1,471 | 21,645 |
| KERN MEDICAL IV, LLC | AT COST | 100,000 | 0 |
| KERN ODYSSEUS LLC | AT COST | 200,742 | 100,000 |
| KNOPP BIOSCIENCES LLC | AT COST | 15,255 | 1,856,250 |
| MIDNIGHT PHARMA, LLC | AT COST | 200,927 | 55,590 |
| NEXGEN VENTURES FUND II, LP | AT COST | 100,638 | 276,839 |
| ON FUND I, A SERIES OF PATHBREAKER SPV, LP | AT COST | 50,269 | 253,380 |
| ON FUND II, A SERIES OF PATHBREAKER SPV, LP | AT COST | 75,508 | 50,269 |
| OR FUND I, A SERIES OF PATHBREAKER SPV, LP | AT COST | 385,333 | 75,509 |
| PATHBREAKER VENTURES FUND II LP | AT COST | 497,819 | 657,596 |
| PORTFOLIO ADVISORS SECONDARY FUND III, L.P. | AT COST | 21,916 | 746,756 |
| RA CAPITAL HEALTHCARE FUND, LP | AT COST | 428,996 | 39,420 |
| RELEVANCE CAPITAL III LP | AT COST | 772,145 | 839,359 |
| RESOLUTE CAPITAL PARTNERS FUND IV, L.P. | AT COST | 0 | 1,068,188 |
| RESOURCE LAND FUND, III, LLC | AT COST | 616,366 | 0 |
| RIVER VII | AT COST | 89,135 | 1,039,378 |
| RIVER VIII, L.P. | AT COST | 75,111 | 113,935 |
| RU FUND III, A SERIES OF PATHBREAKDER SPV, LP | AT COST | 500,655 | 0 |
| SATURN FIVE FRONTIER I LLC | AT COST | 108,754 | 631,440 |
| SI FUND III, A SERIES OF PATHBREAKER SPV, LP | AT COST | 52,136 | 114,118 |
| SI FUND IV, A SERIES OF PATHBREAKER SPV II, LP | AT COST | 413,328 | 50,254 |
| SIGNIA VENTURE PARTNERS III, LP | AT COST | 100,970 | 427,303 |
| TO FUND I, A SERIES OF PATHBREAKER SPV, LP | AT COST | 358,630 | 209,482 |
| VALOR OPPORTUNITY FUND I LP | AT COST | 195,648 | 419,970 |
| VALOR OPPORTUNITY FUND II, LP | AT COST | 449,889 | 200,070 |
| VALOR VENTURE FUND II LP | AT COST | 510,537 | 2,737,770 |
| VALOR VENTURE FUND III LP | AT COST | 306,325 | 861,763 |
| VALOR VENTURE FUND IV, L.P. | AT COST | 0 | 342,683 |
| NORTH AVENUE CAPITAL EQUITY | AT COST | 3,587 | 66,382 |
| RIVER VI, L.P. | AT COST | 0 | 5,238 |
| RITCHIE ENERGY, LLC | AT COST | 0 | 23,299 |
| Description | Beginning of Year - Book Value | End of Year - Book Value | End of Year - Fair Market Value |
|---|---|---|---|
| RECEIVABLE - TAX WITHHELD FULCRUM | 16,636 | 0 | 0 |
| Description | Revenue and Expenses per Books | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| PORTFOLIO DEDUCTIONS THROUGH PARTNERSHIPS | 279,937 | 279,937 | 0 | |
| INVESTMENT INTEREST THROUGH PARTNERSHIPS | 39,957 | 39,957 | 0 | |
| OTHER PARTNERSHIP DEDUCTIONS | 14,861 | 14,861 | 0 | |
| NON DEDUCTIBLE EXPENSES THROUGH PARTNERSHIPS | 4,930 | 0 | 0 | |
| OFFICE EXPENSE REIMBURSEMENTS | 55,684 | 23,825 | 31,859 | |
| BANK CHARGE & WIRE FEE | 2,571 | 1,928 | 643 | |
| TECHNOLOGY FEES | 750 | 375 | 375 | |
| INSURANCE | 4,742 | 0 | 4,742 |
| Description | Revenue And Expenses Per Books | Net Investment Income | Adjusted Net Income |
|---|---|---|---|
| PARTNERSHIPS ROYALTIES | 54 | 54 | 54 |
| OTHER MISC INCOME | 239 | 239 | 239 |
| PARTNERSHIPS OTHER PORTFOLIO INC | 94,440 | 94,440 | 94,440 |
| PARTNERSHIPS OTHER INCOME | 3,093 | 3,093 | 3,093 |
| UNRELATED BUSINESS INCOME | 65,972 | 0 | 65,972 |
| PARTNERSHIPS ORDINARY INCOME | 7,398 | 7,398 | 7,398 |
| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| INVESTMENT MANAGEMENT FEES | 24,912 | 24,912 | 0 |
| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| FOREIGN TAX WITHHELD FROM INCOME | 4,230 | 4,230 | 0 | |
| FOREIGN TAX WITHHELD THROUGH PARTNERSHIPS | 933 | 933 | 0 |